Advances in the management of dyslipidemia

Current Opinion in Cardiology
June KampangkaewVijay Nambi

Abstract

Cardiovascular disease is the leading cause of morbidity and mortality in the United States and therapies aimed at lipid modification are important for the reduction of cardiovascular risk. There have been many exciting advances in lipid management over the recent years. This review discusses these recent advances as well as the direction of future studies. Several recent clinical trials support low-density lipoprotein cholesterol (LDL-c) reduction beyond maximal statin therapy for improved cardiovascular outcomes. Ezetimibe reduced LDL-c beyond maximal statin therapy and was associated with improved cardiovascular outcomes for high-risk populations. Further LDL-c reduction may also be achieved with proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibition and a recent trial, Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER), was the first to show reduction in cardiovascular events for evolocumab. Additional outcome studies of monoclonal antibody and RNA-targeted PCSK9 inhibitors are underway. Quantitative high-density lipoprotein cholesterol (HDL-c) improvements have failed to have clinical impact to date; most recently, cholesteryl ester transfer protein inhibitors ...Continue Reading

References

Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Mar 22, 2003·Biochimica Et Biophysica Acta·Frank W Pfrieger
Mar 1, 1960·American Journal of Public Health and the Nation's Health·J STAMLER
Nov 6, 2003·JAMA : the Journal of the American Medical Association·Steven E NissenRichard Kerensky
Jan 24, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Ronald W ClarkMark J Bamberger
Feb 7, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Ingemar Björkhem, Steve Meaney
Nov 9, 2004·Atherosclerosis. Supplements·T R PedersenUNKNOWN Scandinavian Simvastatin Survival Study Group
Jan 19, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Alan R TallNan Wang
May 18, 2010·Neuroscience and Biobehavioral Reviews·Bernard G Schreurs
Oct 15, 2010·The New England Journal of Medicine·Kiran MusunuruSekar Kathiresan
Nov 19, 2010·The New England Journal of Medicine·Christopher P CannonUNKNOWN Determining the Efficacy and Tolerability Investigators
Jul 5, 2012·Women's Health·Lydia E Pace, Eleanor Bimla Schwarz
Nov 7, 2012·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN dal-OUTCOMES Investigators
May 4, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Anastasia GeorgiadiSander Kersten
Jun 25, 2014·Nature Reviews. Cardiology·Razvan T Dadu, Christie M Ballantyne
Aug 12, 2014·Current Opinion in Lipidology·Thomas A Lagace
Nov 19, 2014·The New England Journal of Medicine·Anand RohatgiPhilip W Shaul
Feb 16, 2015·Protein & Cell·Juan Zhang, Qiang Liu
Mar 17, 2015·The New England Journal of Medicine·Jennifer G RobinsonUNKNOWN ODYSSEY LONG TERM Investigators
Mar 17, 2015·The New England Journal of Medicine·Marc S SabatineUNKNOWN Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Jul 30, 2015·The New England Journal of Medicine·Daniel GaudetJohn J P Kastelein
Oct 8, 2015·The New England Journal of Medicine·Brendan M EverettWilliam R Hiatt
Apr 5, 2016·The New England Journal of Medicine·Salim YusufUNKNOWN HOPE-3 Investigators
Jul 22, 2016·Diabetes Care·Rafael Bitzur
Oct 30, 2016·Australian Prescriber·Michael M Page, Gerald F Watts
Nov 16, 2016·JAMA : the Journal of the American Medical Association·Stephen J NichollsSteven E Nissen
Mar 16, 2017·Clinical Cardiology·Deepak L BhattUNKNOWN REDUCE-IT Investigators
Mar 18, 2017·The New England Journal of Medicine·Kausik K RayJohn J P Kastelein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.